Amylyx Pharmaceuticals, Inc. (AMLX)
CautionA data-driven read of AMLX's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
Signals are mixed: 3 of 5 available lean bullish, 2 lean bearish.
Every trading day in the last 2 years where AMLX moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 28, 2026 | -6.56% | $34.74 |
| Aug 19, 2026 | +80.12% | $38.60 |
| Aug 11, 2026 | +4.23% | $23.63 |
| Aug 7, 2026 | -5.66% | $22.82 |
| Aug 6, 2026 | +10.71% | $24.19 |
| Aug 4, 2026 | +8.43% | $21.87 |
| Jul 30, 2026 | +5.17% | $20.75 |
| Jul 27, 2026 | +5.87% | $19.49 |
| Jul 24, 2026 | +4.66% | $18.41 |
| Jul 22, 2026 | -4.32% | $17.70 |
| Jul 21, 2026 | +6.02% | $18.50 |
| Jul 17, 2026 | +4.29% | $17.75 |
| Jul 16, 2026 | -4.27% | $17.02 |
| Jul 14, 2026 | +4.54% | $18.20 |
| Jun 29, 2026 | +5.12% | $18.70 |
| Jun 15, 2026 | +4.11% | $15.19 |
| Jun 12, 2026 | +4.89% | $14.59 |
| Jun 9, 2026 | +4.15% | $13.55 |
| Jun 5, 2026 | -6.92% | $13.32 |
| Jun 4, 2026 | +8.41% | $14.31 |
| Jun 2, 2026 | -5.54% | $13.29 |
| May 20, 2026 | +6.83% | $13.61 |
| May 15, 2026 | -4.32% | $13.28 |
| May 14, 2026 | -4.80% | $13.88 |
| May 7, 2026 | -5.35% | $15.20 |
Showing the 25 most recent of 160 on record. Full history is on the Price Insights page.
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
55 Cambridge Parkway, Cambridge, MA, 02142, United States, 617 682 0917
A complete statistical profile built from AMLX's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.